ELOHIMED is a French SME specializing in the research and development of new drugs and bioactive compositions.

Our composition is patented in Europe under number EP4119134 (12/19/2025), in France under number FR2103144, in the USA under number US 11,918,591 B2 (03/05/2024). This composition according to the invention, destructures and restructures the lipid composition of cells, and in particular of the membrane lipid rafts, targets of the enveloped pathogens, and could therefore prevent the setting up of a fusion complex, the formation of synapses, the endocytosis, and thus in the long run, the penetration of the enveloped pathogens into the cells. Preclinical trials have been carried out with very interesting results, particularly on SARS-CoV2, on a virus from the lentivirus family (HIV), on Influenza viruses (H1N1).

Attached Report Results 20.0451: Testing the effectiveness of the composition in the presence of HepG2 cells and eGFP-lentivirus (HIV, enveloped virus) compared to the Raltegravir (ISENTRESS)/Tenofovir(VIREAD) combination. The results show a significant and positive effect of combination 2 at dose 3 (page 13). The eGFP marker allows to see if the virus crosses the membrane of HepG2 cells.

The Sars-Cov2 report from the University of Basel (Switzerland) highlighted the effectiveness of different combinations on the WUHAN and DELTA strains of Sars-CoV2 (enveloped virus).

Preclinical trials conducted at the Lille University Hospital, virology department, on the H1N1 influenza virus (enveloped virus) showed a significant reduction in virus per milliliter of sample, practically 1000 (3log10) at MOI 0.01.

On the other hand, some viruses can cause chronic inflammation, sepsis, impaired cell function that can lead to cancer, etc., resulting in an increase in morbidity and mortality leading to serious long-term residual damage. This innovative composition allows us to solve these problems.

Our project aims to develop a new drug indicated for the prevention or treatment of enveloped virus infections, their mutants, and associated complications. To this end, we are seeking Consortium through the HORIZON-HLTH-2026-01-DISEASE-03 call for projects to optimize in vivo preclinical development and the various clinical phases leading to commercialization.